These clinical practice guidelines for the diagnosis and management of von Willebrand disease (VWD) were developed in collaboration with the American Society for Hematology (ASH), the International Society on Thrombosis and Haemostasis (ISTH), and National Hemophilia Foundation (NHF) and published in the journal Blood Advances. The two development panels, one for diagnosis and one for management, were made up of 32 VWD experts from around the world and included people with VWD, adult and pediatric hematologists, obstetrician/gynecologists, internists, a dentist, a nephrologist, laboratory specialists, and scientists with expertise in evidence synthesis and appraisal and guideline development methodology. A systematic review of available evidence was conducted by the University of Kansas Medical Center and the panels referred to this evidence to make recommendations as well as to identify key areas where more research is required.
These recommendations offer important guidance on prophylaxis, major and minor surgeries, heavy menstrual and postpartum bleeding, diagnostic thresholds, genetic testing, and much more. They constitute a valuable resource for clinicians and people with VWD in their shared decision making about individual care. They also form a solid foundation for the essential advocacy work to improve access to the recommended diagnostic techniques and treatment options in all countries.
Read the commentary on the guidelines, by Barbara Konkle and Steven Pipe, in Haemophilia.
All four of the collaborating organizations are creating resources to support the implementation of the guidelines. Use the links below to access these resources and check back often to see which new ones have been added.